FIA
AXDX

FNY Investment Advisers’s Accelerate Diagnostics AXDX Stock Holding History

FNY Investment Advisers’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,000
Closed -$5.22K – 454
2024
Q1 		$4 Buy
+5,000
New +$7.9K ﹤0.01% 530

Other funds holding AXDX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Investment Advisers's AXDX Position: Q2 2024 in Review

FNY Investment Advisers sold out of Accelerate Diagnostics (AXDX) in Q2 2024, closing a stake of 5,000 shares — an estimated $5.22K sold.

FNY Investment Advisers first reported a position in AXDX in Q1 2024 and held it in 1 quarter. The position peaked at $4 in Q1 2024. 41 funds tracked by Wall St. Rank hold AXDX as of Q2 2024.

  • FNY Investment Advisers reported no remaining Accelerate Diagnostics position as of Q2 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 5,000 Accelerate Diagnostics shares in Q2 2024, an estimated $5.22K.
  • FNY Investment Advisers first reported a position in Accelerate Diagnostics in Q1 2024 and held it in 1 quarter.
  • FNY Investment Advisers's Accelerate Diagnostics position peaked at $4 in Q1 2024.
  • 41 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2024.

Based on FNY Investment Advisers's 13F filing for Q2 2024, filed 5 Aug 2024.